A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The combination of docetaxel and gemcitabine has shown significant activity in patients with
metastatic breast cancer. Several studies have activity in patients of multiple lines of
therapy, including patients that have been treated with prior taxane therapy. Overall
responses have ranged from 30% to 79%. The major side effects of the combination chemotherapy
have been neutropenia, anemia, asthenia, neuropathy, nausea, mucositis, and neutropenic fever